Free shipping on all orders over $ 500

Felezonexor (CBS9106)

Cat. No. M21722
Felezonexor (CBS9106) Structure
Synonym:

CBS9106; SL-801

Size Price Availability Quantity
10mg USD 1250  USD1250 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Felezonexor (CBS9106; SL-801) is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity without affecting CRM1 mRNA levels. This effect could be reversed by adding bortezomib or LMB. Felezonexor (CBS9106) inhibits CRM1-dependent nuclear export, causing arrest of the cell cycle and inducing apoptosis in a time- and dose-dependent manner for a broad spectrum of cancer cells, including multiple myeloma cells.

Felezonexor is also a reversible inhibitor of XPO1, inhibits nuclear export by covalently binding to Cys528 as well as by inducing the degradation of XPO1.

Oral administration of Felezonexor (CBS9106) significantly suppresses tumor growth and prolongs survival in mice bearing tumor xenograft without a significant loss in body weight. A reduced level of CRM1 protein is also observed in tumor xenografts isolated from mice treated with Felezonexor (CBS9106).

Chemical Information
Molecular Weight 419.83
Formula C18H21ClF3N3O3
CAS Number 1076235-04-5
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yuqin Lei, et al. J Med Chem. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1

[2] Asfar S Azmi, et al. Nat Rev Clin Oncol . The nuclear export protein XPO1 - from biology to targeted therapy

[3] Giovanni Luca Gravina, et al. J Hematol Oncol. Nucleo-cytoplasmic transport as a therapeutic target of cancer

[4] Naoya Saito, et al. Mol Cancer Ther . CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway

[5] Naoya Saito, et al. Mol Cancer Ther. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway

[6] Joel G Turner, et al. Biochem Pharmacol. Nuclear export of proteins and drug resistance in cancer

[7] Keiichi Sakakibara, et al. Blood . CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

[8] Keiichi Sakakibara, et al. Blood. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

Related CRM1 Products
CRM1-IN-2

CRM1-IN-2 is a noncovalent CRM1 inhibitor.

CRM1-IN-1

CRM1-IN-1 is a noncovalent CRM1 inhibitor.

KPT-251 

KPT-251 is an orally active chromosome region maintenance 1 protein (CRM1) inhibitor. KPT-251 induces cancer cell apoptosis and shows antileukemic activity.

Eltanexor

Eltanexor, also known as KPT-8602, is a second-generation exportin-1 (CRM1) inhibitor with IC50 values of 20−211 nM in 10 AML lines.

  Catalog
Abmole Inhibitor Catalog




Keywords: Felezonexor (CBS9106), CBS9106; SL-801 supplier, CRM1, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.